AssetMark’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
Other funds holding XENE
AssetMark's XENE Position: Q3 2026 in Review
AssetMark reduced its Xenon Pharmaceuticals (XENE) stake by 12% in Q3 2026, selling an estimated $142K and leaving 16,952 shares worth $630K. The position accounts for ﹤0.01% of the portfolio, ranked #1192.
AssetMark first reported a position in XENE in Q2 2023 and has held it in 14 quarters since. The position peaked at $1.18M in Q1 2026. 196 funds tracked by Wall St. Rank hold XENE as of Q3 2026.
- AssetMark held 16,952 shares of Xenon Pharmaceuticals worth $630K as of Q3 2026.
- AssetMark sold 2,382 Xenon Pharmaceuticals shares in Q3 2026, an estimated $142K.
- Xenon Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1192 holding.
- AssetMark first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 14 quarters since.
- AssetMark's Xenon Pharmaceuticals position peaked at $1.18M in Q1 2026.
- 196 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.